BTIG Research initiated coverage on Zoetis with a new price target
$ZTS
Biotechnology: Pharmaceutical Preparations
Health Care
BTIG Research initiated coverage of Zoetis with a rating of Buy and set a new price target of $220.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/25/2024 | $220.00 | Buy | BTIG Research |
| 1/12/2024 | $195.00 → $215.00 | Buy | Stifel |
| 12/19/2023 | $230.00 | Buy | Jefferies |
| 12/7/2023 | $237.00 | Outperform | Exane BNP Paribas |
| 9/6/2023 | $230.00 | Buy | HSBC Securities |
| 7/12/2022 | $205.00 | Overweight | Piper Sandler |
| 3/9/2022 | $232.00 → $208.00 | Neutral | Citigroup |
| 12/20/2021 | $184.00 → $232.00 | Neutral | Citigroup |
SC 13G/A - Zoetis Inc. (0001555280) (Subject)
SC 13G/A - Zoetis Inc. (0001555280) (Subject)
SC 13G/A - Zoetis Inc. (0001555280) (Subject)
3 - Zoetis Inc. (0001555280) (Issuer)
4 - Zoetis Inc. (0001555280) (Issuer)
4 - Zoetis Inc. (0001555280) (Issuer)
10-Q - Zoetis Inc. (0001555280) (Filer)
8-K - Zoetis Inc. (0001555280) (Filer)
8-K - Zoetis Inc. (0001555280) (Filer)
Zoetis Inc. (NYSE:ZTS) will participate in the Piper Sandler 36th Annual Healthcare Conference on Tuesday, December 3, 2024. Wetteny Joseph, Executive Vice President and Chief Financial Officer, will represent the company and respond to questions from analysts at 11:30 a.m. ET. Investors and other interested parties will be able to access a live audio webcast of the session by visiting http://investor.zoetis.com/events-presentations. A replay will also be available on the Zoetis website at the conclusion of the event. About Zoetis As the world's leading animal health company, Zoetis is driven by a singular purpose: to nurture our world and humankind by advancing care for animals. Afte
New Commercial Organizational Structure to Accelerate Long-Term Growth Strategy in Key Markets and Optimize Global Commercial Operations Zoetis Inc. (NYSE:ZTS) today announced the appointment of Jamie Brannan to a newly created role of Chief Commercial Officer, overseeing all commercial markets across the globe for the world's leading animal health company. In this new role, Mr. Brannan will lead an evolved commercial organizational structure that will accelerate the company's long-term growth strategy across key markets, drive greater global commercial collaboration and unlock future growth opportunities. This press release features multimedia. View the full release here: https://www.bu
Zoetis Inc. (NYSE:ZTS) will participate in the Jefferies London Healthcare Conference on Wednesday, November 20, 2024. Wetteny Joseph, Executive Vice President and Chief Financial Officer, will represent the company and respond to questions from analysts at 3:00 p.m. GMT. Investors and other interested parties will be able to access a live audio webcast of the session by visiting http://investor.zoetis.com/events-presentations. A replay will also be available on the Zoetis website at the conclusion of the event. About Zoetis As the world's leading animal health company, Zoetis is driven by a singular purpose: to nurture our world and humankind by advancing care for animals. After innovati
BTIG Research initiated coverage of Zoetis with a rating of Buy and set a new price target of $220.00
Stifel reiterated coverage of Zoetis with a rating of Buy and set a new price target of $215.00 from $195.00 previously
Jefferies resumed coverage of Zoetis with a rating of Buy and set a new price target of $230.00
Across the recent three months, 4 analysts have shared their insights on Zoetis (NYSE:ZTS), expressing a variety of opinions spanning from bullish to bearish. Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 4 0 0 0 0 Last 30D 1 0 0 0 0 1M Ago 0 0 0 0 0 2M Ago 0 0 0 0 0 3M Ago 3 0 0 0 0 In the assessment of 12-month price targets, analysts unveil insights for Zoetis, presenting an average target of $205.25, a high estimate of $225.00, and a low estimate of $180.00. A negative shift in sentiment
BTIG analyst Mark Massaro initiates coverage on Zoetis (NYSE:ZTS) with a Buy rating and announces Price Target of $220.
Zoetis (NYSE:ZTS) has outperformed the market over the past 10 years by 7.71% on an annualized basis producing an average annual return of 18.4%. Currently, Zoetis has a market capitalization of $81.78 billion. Buying $1000 In ZTS: If an investor had bought $1000 of ZTS stock 10 years ago, it would be worth $5,424.03 today based on a price of $179.23 for ZTS at the time of writing. Zoetis's Performance Over Last 10 Years Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time. This article was generated by Benzinga's automated content engine and reviewed by
New Commercial Organizational Structure to Accelerate Long-Term Growth Strategy in Key Markets and Optimize Global Commercial Operations Zoetis Inc. (NYSE:ZTS) today announced the appointment of Jamie Brannan to a newly created role of Chief Commercial Officer, overseeing all commercial markets across the globe for the world's leading animal health company. In this new role, Mr. Brannan will lead an evolved commercial organizational structure that will accelerate the company's long-term growth strategy across key markets, drive greater global commercial collaboration and unlock future growth opportunities. This press release features multimedia. View the full release here: https://www.bu
Molson Coors' President and Chief Executive Officer brings valuable business leadership and global public company experience to Zoetis Board Zoetis Inc. (NYSE:ZTS) today announced the appointment of Gavin D.K. Hattersley, President, Chief Executive Officer and Director of Molson Coors Beverage Company, to its Board of Directors. Mr. Hattersley brings global public company leadership and board experience, including as a current Chief Executive Officer and former Chief Financial Officer of Molson Coors, to the Zoetis Board. He will serve on the Board's Corporate Governance and Sustainability Committee. "Gavin Hattersley brings invaluable experience to our Board as we continue to expand
Animal welfare nonprofit bolsters board to better serve the needs of pet lovers nationally SAN ANTONIO, Nov. 14, 2023 /PRNewswire/ -- Petco Love welcomes new members to its board of directors, tapping a wide range of expertise to support its lifesaving mission. Petco Love is committed to shared social values and its diverse and inclusive board composition is a significant reflection of the unified values of its communities served nationwide. Since its founding more than 20 years ago, Petco Love excels as a leader and valued partner in animal welfare by creating a better world
Reports Revenue of $2.4 Billion, Growing 11%, and Net Income of $682 Million, or $1.50 per Diluted Share, Increasing 14% and 16%, Respectively, on a Reported Basis for Third Quarter 2024 Delivers 14% Operational Growth in Revenue and 15% Operational Growth in Adjusted Net Income for Third Quarter 2024 Reports Adjusted Net Income of $716 Million, or Adjusted Diluted EPS of $1.58, for Third Quarter 2024 Raises Full Year 2024 Revenue Guidance to $9.200 - $9.300 Billion, Representing Operational Revenue Growth of 10% to 11%, with Diluted EPS on an Adjusted Basis of $5.86 to $5.92 Updates Full Year Operational Growth in Adjusted Net Income to 13.5% to 14.5% Zoetis Inc. (NYSE:ZTS)
The Board of Directors of Zoetis Inc. (NYSE:ZTS) has declared a dividend of $0.432 per share for the fourth quarter of 2024. The dividend will be paid on Tuesday, December 3, 2024, to all holders of record of the Company's common stock as of the close of business on Thursday, October 31, 2024. About Zoetis As the world's leading animal health company, Zoetis is driven by a singular purpose: to nurture our world and humankind by advancing care for animals. After innovating ways to predict, prevent, detect, and treat animal illness for more than 70 years, Zoetis continues to stand by those raising and caring for animals worldwide – from veterinarians and pet owners to livestock farmers and
Zoetis Inc. (NYSE:ZTS) will host a webcast and conference call at 8:30 a.m. (ET) on Monday, November 4, 2024. Chief Executive Officer Kristin Peck and Executive Vice President and Chief Financial Officer Wetteny Joseph will review third quarter 2024 financial results and respond to questions from financial analysts during the call. Investors and the public may access the live webcast by visiting the Zoetis website at http://investor.zoetis.com/events-presentations. Information on accessing and pre-registering for the webcast is available beginning today. A replay of the webcast will be made available on November 4, 2024. About Zoetis As the world's leading animal health company, Zoetis is
For Immediate Release: January 13, 2022 Today, the U.S. Food and Drug Administration approved Solensia (frunevetmab injection), the first treatment for the control of pain associated with osteoarthritis in cats and the first monoclonal antibody (mAb) new animal drug approved by the FDA for use in any animal species. Frunevetmab, the active ingredient in Solensia, is a cat-specific monoclonal antibody (a type o